AlphAIAlphAI — Financial news for AI agents
grafa.com$RMD

ResMed revenue up 6% to $1.4B in Q1 FY27

ResMed reported Q1 FY27 revenue of $1.4B, up 6% YoY, with GAAP EPS rising 23% to $2.92. Growth driven by global demand for sleep and breathing solutions. The company returned $1B to shareholders via buybacks and dividends. ResMed's share price remained at $35.38 post-announcement.

Original reporting
grafa.com
Published Oct 29, 2026, 11:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ResMed revenue up 6% to $1.4B in Q1 FY27 — source image
Source · grafa.com
Decision brief

The 30-second read

$RMDBullishMed
01

Why it matters

The earnings beat reinforces the company's growth narrative but the lack of price movement suggests market neutrality pending further guidance.

02

Market read

ResMed's earnings provide fresh data for health‑care investors and may influence sector sentiment, though immediate price impact appears muted.

03

What to watch

The $1B buyback and dividend return may attract income‑focused investors, a factor not emphasized in the release.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

ResMed is a leading provider of sleep and respiratory care devices, listed on the ASX with a US ADR (RMD).

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

ResMed reported Q1 FY27 revenue of $1.4B, 6% growth and EPS of $2.92, the first public disclosure of these results.

Expected impact

likely modest pressure as market prices in the earnings beat without a clear directional catalyst

Evidence & confidence

The earnings numbers are positive but the stock opened flat, indicating traders may wait for guidance or further data.

Market effects

Sector

Strong demand for sleep and breathing solutions may support the broader medical device sector.

Regional

Positive earnings from an Australian‑listed firm could boost sentiment in the ASX health‑care segment.

Global

ResMed's digital health expansion may influence global tele‑health trends.

Counterpoint

What could challenge this read

Despite earnings beat, the flat share price could signal underlying concerns about growth sustainability.

Key entities

  • Executive
    Mick Farrell

    Chairman and CEO of ResMed, quoted in the earnings release.

  • Executive
    Carol Burt

    Appointed lead director of ResMed's board effective Nov. 15.

Read at source← All news

StoryResMed posts Q1 FY27 beat with $1.4 B revenue, $2.91 EPS and $1 B returned to shareholders

Also covered by

4 outlets

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com